Insider · CIK 0000902132
Daniel J Starks
Files at ABT (ABBOTT LABORATORIES). First filing Oct 30, 2023, latest Apr 28, 2026.
In brief
Daniel J Starks files SEC Form 4 as director at ABT (ABBOTT LABORATORIES). Since Oct 30, 2023, Daniel J Starks has reported 2 open-market buys worth $2.0M and 1 open-market sell worth $4.7M, the latest filed on Apr 28, 2026.
A track record needs three past buys with six months of prices behind them; Daniel J Starks has 1, so none is measured yet.
The newest scored trade: bought $927k of ABT on Apr 27, 2026, filed Apr 28, 2026, scored 72 (notable). In the last 12 months: 2 buys worth $2.0M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ABT: ABBOTT LABORATORIES
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 72Notable | ABBOTT LABORATORIES | $927k 10,000 shares | +0% | +2% from low-31% from high | |
| 57Moderate | ABBOTT LABORATORIES | $1.1M 10,000 shares | +0% | +2% from low-21% from high | |
| 20Weak | ABBOTT LABORATORIES | $4.7M 50,000 shares | -1% | +4% from low-18% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 26, 2023 | ABT ABBOTT LABORATORIES | 50,000 0.00% of outstanding | $4.7M | Oct 26, 2023 | $5.7M |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 24, 2026 | ABT ABBOTT LABORATORIES | AGrant or award Common shares without par value | +2,286 | $0.00 | $0 | 6,741,103 | Apr 28, 2026 |
| Apr 27, 2026 | ABT ABBOTT LABORATORIES | POpen-market purchase Common shares without par value | +10,000 | $92.65 | $927k | 6,751,103 | Apr 28, 2026 |
| Apr 24, 2026 | ABT ABBOTT LABORATORIES | AGrant or award Option (right to buy)derivative | +7,105 | $0.00 | $0 | 7,105 | Apr 28, 2026 |
| Feb 4, 2026 | ABT ABBOTT LABORATORIES | POpen-market purchase Common shares without par value | +4,967 | $109.14 | $542k | 6,733,784 | Feb 6, 2026 |
| Feb 4, 2026 | ABT ABBOTT LABORATORIES | POpen-market purchase Common shares without par value | +5,033 | $108.33 | $545k | 6,738,817 | Feb 6, 2026 |
| Apr 25, 2025 | ABT ABBOTT LABORATORIES | AGrant or award Common shares without par value | +1,635 | $0.00 | $0 | 6,728,817 | Apr 29, 2025 |
| Apr 25, 2025 | ABT ABBOTT LABORATORIES | AGrant or award Option (right to buy)derivative | +4,516 | $0.00 | $0 | 4,516 | Apr 29, 2025 |
| Oct 26, 2023 | ABT ABBOTT LABORATORIES | SOpen-market sale Common shares without par value10b5-1 | -26,907 | $93.81 | $2.5M | 6,748,409 | Oct 30, 2023 |
| Oct 26, 2023 | ABT ABBOTT LABORATORIES | SOpen-market sale Common shares without par value10b5-1 | -23,093 | $94.33 | $2.2M | 6,725,316 | Oct 30, 2023 |
Questions about Daniel J Starks
Answered from the filings on this page, as of the latest one.
Is Daniel J Starks buying or selling?
In the last 12 months Daniel J Starks reported 2 open-market buys worth $2.0M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $927k of ABT on Apr 27, 2026. Grants, option exercises and tax withholding are not counted.
How did Daniel J Starks's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Daniel J Starks has 1.
Where does Daniel J Starks file Form 4?
Daniel J Starks has filed Form 4 at ABT (ABBOTT LABORATORIES). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.